利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.012 秒)

    TNF-muteins
    1.
    发明授权
    TNF-muteins 失效
    TNF-突变蛋白

    公开(公告)号：US5422104A

    公开(公告)日：1995-06-06

    申请号：US794400

    申请日：1991-11-20

    申请人： Walter Fiers ,  Jan Tavernier ,  Xaveer Van Ostade

    发明人： Walter Fiers ,  Jan Tavernier ,  Xaveer Van Ostade

    IPC分类号： A61K38/00 ,  A61P35/00 ,  C07K14/52 ,  C07K14/525 ,  C12N1/21 ,  C12N15/09 ,  C12N15/28 ,  C12P21/02 ,  C12R1/19 ,  A61K45/05 ,  C12P21/06

    CPC分类号： C07K14/525 ,  A61K38/00

    摘要： It is an object of this invention to provide a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof characterized in that the TNF sequence is changed by a deletion, insertion, substitution or combinations thereof, of one or more amino acids so that the mutein shows a significant difference between its binding affinity to the human p75-Tumor-Necrosis-Factor-Receptor and to the human p55-Tumor-Necrosis-Factor-Receptor. The invention also includes DNA sequences coding for such muteins, vectors comprising such DNA sequences, host cells transformed with such vectors and a process for the production of such muteins employing such transformed host cells and pharmaceutical compositions containing such muteins and their use for the treatment of illnesses, for example cancer.

    摘要翻译： 本发明的目的是提供一种人肿瘤坏死因子突变蛋白或其药学上可接受的盐，其特征在于通过其一个或多个氨基酸的缺失，插入，取代或组合改变TNF序列，使得突变蛋白 显示其与人p75-肿瘤坏死因子受体和人p55-肿瘤坏死因子受体的结合亲和力之间的显着差异。 本发明还包括编码这种突变蛋白的DNA序列，包含这种DNA序列的载体，用这种载体转化的宿主细胞和使用这种转化的宿主细胞产生这种突变蛋白的方法和含有这种突变蛋白的药物组合物及其用于治疗 疾病，例如癌症。

    DNAs encoding tumor necrosis factor-.alpha. muteins
    3.
    发明授权
    DNAs encoding tumor necrosis factor-.alpha. muteins 失效
    编码肿瘤坏死因子-α突变蛋白的DNA

    公开(公告)号：US5652353A

    公开(公告)日：1997-07-29

    申请号：US397470

    申请日：1995-03-01

    申请人： Walter Fiers ,  Jan Tavernier ,  Xaveer Van Ostade

    发明人： Walter Fiers ,  Jan Tavernier ,  Xaveer Van Ostade

    IPC分类号： A61K38/00 ,  A61P35/00 ,  C07K14/52 ,  C07K14/525 ,  C12N1/21 ,  C12N15/09 ,  C12N15/28 ,  C12P21/02 ,  C12R1/19

    CPC分类号： C07K14/525 ,  A61K38/00

    摘要： It is an object of this invention to provide a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof characterized in that the TNF sequence is changed by a deletion, insertion, substitution or combinations thereof, of one or more amino acids so that the mutein shows a significant difference between its binding affinity to the human p75-Tumor-Necrosis-Factor-Receptor and to the human p55-Tumor-Necrosis-Factor-Receptor. The invention also includes DNA sequences coding for such muteins, vectors comprising such DNA sequences, host cells transformed with such vectors and a process for the production of such muteins employing such transformed host cells and pharmaceutical compositions containing such muteins and their use for the treatment of illnesses, for example cancer.

    摘要翻译： 本发明的目的是提供一种人肿瘤坏死因子突变蛋白或其药学上可接受的盐，其特征在于通过其一个或多个氨基酸的缺失，插入，取代或组合改变TNF序列，使得突变蛋白 显示其与人p75-肿瘤坏死因子受体和人p55-肿瘤坏死因子受体的结合亲和力之间的显着差异。 本发明还包括编码这种突变蛋白的DNA序列，包含这种DNA序列的载体，用这种载体转化的宿主细胞和使用这种转化的宿主细胞产生这种突变蛋白的方法和含有这种突变蛋白的药物组合物及其用于治疗 疾病，例如癌症。